Patient-Reported Outcomes in Psoriatic Arthritis

Orbai, Ana‐Maria; Ogdie, Alexis

doi:10.1016/j.rdc.2016.01.002

Cited by 56 publications

(53 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although clinical and laboratory variables are used to measure disease activity and severity, patient-reported outcome (PRO) measures are equally important and represent a critical firsthand account of the patient's perception of well-being and response to treatment 13 . Some of the PRO instruments used in PsA clinical trials were initially created for other diseases 14,15,16,17 ; other generic PRO instruments are also used in PsA trials with the goal of characterizing overall population health, including the Medical Outcomes Study 36-Item Short Form Survey (SF-36) 18 .…”

Section: Rheumatologymentioning

confidence: 99%

Evaluation of Self-reported Patient Experiences: Insights from Digital Patient Communities in Psoriatic Arthritis

Sunkureddi

Doogan²,

Heid³

et al. 2018

J Rheumatol

Self Cite

View full text Add to dashboard Cite

Objective.To evaluate the types of experiences and treatment access challenges of patients with psoriatic arthritis (PsA) using self-reported online narratives.Methods.English-language patient narratives reported between January 2010 and May 2016 were collected from 31 online sources (general health social networking sites, disease-focused patient forums, treatment reviews, general health forums, mainstream social media sites) for analysis of functional impairment and 40 online sources for assessment of barriers to treatment. Using natural language processing and manual curation, patient-reported experiences were categorized into 6 high-level concepts of functional impairment [social, physical, emotional, cognitive, role activity (SPEC-R), and general] and 6 categories to determine barriers to treatment access (coverage ineligibility, out-of-pocket cost, issues with assistance programs, clinical ineligibility, formulary placement/sequence, doctor guidance). The SPEC-R categorization was also applied to 3 validated PsA patient-reported outcome (PRO) instruments to evaluate their capacity to collect lower-level subconcepts extracted from patient narratives.Results.Of 15,390 narratives collected from 3139 patients with PsA for exploratory analysis, physical concepts were the most common (81.5%), followed by emotional (50.7%), cognitive (20.0%), role activity (8.1%), and social (5.6%) concepts. Cognitive impairments and disease burden on family and parenting were not recorded by PsA PRO instruments. The most commonly cited barriers to treatment were coverage ineligibility (51.6%) and high out-of-pocket expenses (31.7%).Conclusion.Patients often discussed physical and emotional implications of PsA in online platforms; some commonly used PRO instruments in PsA may not identify cognitive issues or parenting/family burden. Nearly one-third of patients with PsA reported access barriers to treatment.

show abstract

Section: Rheumatologymentioning

confidence: 99%

Evaluation of Self-reported Patient Experiences: Insights from Digital Patient Communities in Psoriatic Arthritis

Sunkureddi

Doogan²,

Heid³

et al. 2018

J Rheumatol

Self Cite

View full text Add to dashboard Cite

show abstract

“…[6,10] This is indeed warranted as several of the PROMs with elusive measurement properties are widely used in PsA trials and clinics today. [77] Some COS domains may be more appropriately assessed by non-PROM instruments such as biomarkers and clinical assessments, and parallel work streams within GRAPPA-OMERACT are collecting psychometric evidence for the use of such tools in PsA. These research initiatives will in addition to the psychometric evidence for PsA PROMs presented in this review inform the consecutive stages of developing a COMS for PsA.…”

Section: Discussionmentioning

confidence: 95%

“…While previous studies have provided overviews of commonly used instruments in PsA, [76,77] this review provides a systematic identification, characterization and evidence synthesis of measurement properties of all PROMs evaluated in PsA, which constitutes an important step in the GRAPPA-OMERACT process of developing a PsA COMS.…”

Section: Discussionmentioning

confidence: 99%

A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative

Højgaard

Klokker

Orbai

et al. 2018

Seminars in Arthritis and Rheumatism

Self Cite

View full text Add to dashboard Cite

ReuseThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ABSTRACT Background: An updated psoriatic arthritis (PsA) core outcome set (COS) for randomized controlled trials

show abstract

“…Primary results from the trial have been previously reported. 1 Results: In total, 1090 patients were randomised. Of the 313 patients randomised to ETN, by Week 28 there were 83 partial responders and 39 nonresponders.…”

mentioning

confidence: 99%

“…The RAPID3 was originally developed for use in patients with rheumatoid arthritis, but it may be used in clinical practice to assess disease activity in patients with PsA. 1 The PROMIS10 is a general (nondisease-specific) PRO instrument that measures physical, mental, and social health. 2 Developed for the general population, PROMIS10 has not yet been specifically validated in PsA.…”

mentioning

confidence: 99%

AB0903 Efficacy of tildrakizumab in etanercept partial or nonresponders

Crowley

Papp

Hong

et al. 2018

Psoriatic Arthritis

View full text Add to dashboard Cite

BackgroundEtanercept (ETN) is an anti–tumour necrosis factor (TNF) medication that was among the first biologics approved for psoriasis. Additional medications have been developed or are in development for psoriasis, and patients who do not adequately respond to ETN may benefit from these more recent biologics.ObjectivesHere we report the efficacy of tildrakizumab (TIL), a humanised anti–IL-23p19 monoclonal antibody, as evaluated in patients with moderate to severe chronic plaque psoriasis who were partial (Psoriasis Area and Severity Index [PASI]≥50–<75) or nonresponders (PASI <50) to ETN and subsequently rerandomized to TIL in the phase 3 reSURFACE 2 trial (NCT01729754).MethodsPatients with psoriasis (≥10% body surface area, Physician’s Global Assessment [PGA], and PASI ≥12) participated in reSURFACE 2, a 3-part, 52 week, randomised controlled trial. In Part 1 (Weeks 0–12), patients were randomised to subcutaneous TIL 200 mg, TIL 100 mg, or placebo (PBO) administered at Weeks 0 and 4, or ETN 50 mg administered twice weekly. In Part 2 (Weeks 12–28), TIL and ETN patients remained on the same treatment (TIL administered at Week 16; ETN once weekly), whereas PBO patients were rerandomized to TIL 100 or 200 mg. In Part 3 (Weeks 28–52), ETN responders (PASI ≥75) were discontinued, and partial and nonresponders were switched to TIL 200 mg (administered at Weeks 32, 36, and 48). For this post hoc analysis, the proportion of patients (±SD) with PASI response and PGA response (score of 0 [clear] or 1 [minimal] with at least a 2-grade score reduction from baseline) were determined at Week 52. Primary results from the trial have been previously reported.1 ResultsIn total, 1090 patients were randomised. Of the 313 patients randomised to ETN, by Week 28 there were 83 partial responders and 39 nonresponders. At Week 52 (after 20 weeks of TIL treatment) for ETN partial responders, 75%±5%, 34%±5%, 15%±4%, and 58%±5% had achieved PASI 75, 90, 100, and PGA response of 0/1, respectively, with TIL 200 mg treatment. At Week 52 for ETN nonresponders, 54%±6%, 31%±5%, 10%±3%, and 56%±5% had achieved PASI 75, 90, 100, and PGA response of 0/1, respectively, with TIL 200 mg treatment. Adverse events were similar in patients switched from ETN to TIL at Week 28, compared with the patients who were maintained on TIL through Week 52.ConclusionsA substantial portion of patients with moderate to severe chronic plaque psoriasis who were partial or nonresponders to ETN may respond after switching to treatment with TIL 200 mg. TIL may be a reasonable option for those who do not achieve adequate response to ETN.Reference[1] Reich, et al. Lancet. 2017;390(10091):276–288.AcknowledgementsThis study was funded by Merck and Co., Inc. Editorial support for abstract submission was provided by Fishawack Communications and funded by Sun Pharmaceutical Industries, Inc. Analyses were presented at the American Academy of Dermatology .Annual Meeting, San Diego, California, USA, 2018 Disclosure of InterestJ. Crowley Grant/research support from: Abbvie, Amgen, Sun...

show abstract

Patient-Reported Outcomes in Psoriatic Arthritis

Cited by 56 publications

References 85 publications

Evaluation of Self-reported Patient Experiences: Insights from Digital Patient Communities in Psoriatic Arthritis

Evaluation of Self-reported Patient Experiences: Insights from Digital Patient Communities in Psoriatic Arthritis

A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative

AB0903 Efficacy of tildrakizumab in etanercept partial or nonresponders

Contact Info

Product

Resources

About